Pelthos Therapeutics Inc. (PTHS)
$20.50+0.00%Close
SELLRECOVERY · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $13M
- Beta
- 3.11
- P/E (TTM)
- -0.51
- Short % float
- 78.24%
- Days to cover
- 4.1
- SI change
- +11.6%
- 1W
- -0.49%
- 1M
- -8.60%
- vs SPY 1W
- -1.65%
- vs SPY 1M
- -11.60%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 12
- GROWTH
- 30
- GARP
- 0
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC-131.4%
REV YoY-
ROE-218.9%
EPS YoY-
ROA-52.1%
GROSS55
OP-133
NET-165
[VALUATION]
P/E TTM-0.51
P/E FWD-
SECTOR PE20.47
INDUSTRY PE13.95
P/B-50.65
P/FCF-
EV/EBITDA-1.95
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO1.98
ND/EBITDA-
BETA3.11
Company news
FAQ
- What is LOPJLB’s current signal on PTHS?
- LOPJLB’s latest quantitative signal on Pelthos Therapeutics Inc. (PTHS) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is PTHS in?
- Pelthos Therapeutics Inc. (PTHS) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Pelthos Therapeutics Inc. (PTHS) do?
- Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an …